ZIOPHARM ONCOLOGY INC (62) | Intellectual Property (7)

Browse by Subcategory

License Agreements (7)

Recent Contracts

Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute (Filed With SEC on November 5, 2020)
Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020 (Filed With SEC on November 5, 2020)
Amendment to Patent License Agreement, dated as of January 8, 2020 , by and between the Company and the National Cancer Institute (Filed With SEC on March 2, 2020)
Patent License Agreement, dated as of May 28, 2019, by and between the Company and the National Cancer Institute (Filed With SEC on August 8, 2019)